Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Quetiapine
Drug ID BADD_D01888
Description Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder.[L8546] Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [Clozapine] and [Olanzapine].[A2189]
Indications and Usage Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.[L8546] Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.[A185438,A185447,T685]
Marketing Status approved
ATC Code N05AH04
DrugBank ID DB01224
KEGG ID D08456
MeSH ID D000069348
PubChem ID 5002
TTD Drug ID D0H7KF
NDC Product Code 0310-0530; 16729-145; 16729-149; 16714-453; 16714-454; 0093-8163; 50228-380; 0310-0280; 0310-0283; 60687-327; 65862-877; 68001-182; 68001-183; 68001-185; 80425-0107; 16729-146; 16729-150; 0310-0282; 60687-338; 63629-2479; 63629-2481; 65862-875; 70518-0752; 71093-136; 71205-402; 16729-147; 16714-455; 16714-457; 0093-8162; 42291-695; 42291-698; 42291-700; 43547-020; 0310-0272; 0310-0274; 0310-0278; 0310-0284; 68001-181; 70518-0239; 0310-0279; 60687-382; 65862-874; 71093-137; 0615-7987; 0310-0505; 43547-019; 50090-2830; 60687-349; 60687-371; 63629-2478; 63629-2480; 63629-2482; 63629-7116; 71093-138; 0615-7986; 0615-8119; 16714-452; 16714-456; 0093-8166; 33342-135; 43547-519; 71093-135; 72789-255; 80425-0143; 0093-2063; 0093-8164; 42291-699; 43547-520; 43547-522; 43547-523; 50090-2338; 50228-382; 50228-383; 0310-0271; 68001-184; 70518-0289; 71093-139; 16729-148; 29300-309; 50090-4788; 53002-1516; 0310-0275; 0310-0281; 60687-360; 65862-876; 70518-0570; 71205-026; 71610-702; 0310-0515; 0093-8165; 29300-308; 29300-310; 29300-311; 29300-312; 33342-136; 42291-696; 43547-021; 68001-180; 68788-7186; 70518-2828; 0615-7988; 0310-0520; 0310-0540; 33342-137; 42291-697; 43547-518; 43547-521; 50228-384; 65862-873; 71205-401; 0615-8118; 33342-134; 43547-022; 50228-381; 53002-1529
UNII BGL0JSY5SI
Synonyms Quetiapine Fumarate | Ethanol, 2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)-, (E)-2-butenedioate (2:1) (salt) | Seroquel | ICI 204,636 | ICI-204636 | ICI204636 | ICI 204636 | Quetiapine | 2-(2-(4-dibenzo(b,f)(1,4)thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol
Chemical Information
Molecular Formula C21H25N3O2S
CAS Registry Number 111974-69-7
SMILES C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Inner ear disorder04.04.02.002--Not Available
Parkinson's disease17.01.05.0100.000229%Not Available
Blood disorder01.05.01.0040.000120%Not Available
Adjustment disorder19.23.01.0010.000147%Not Available
Parasomnia19.02.03.0070.000185%Not Available
Psychotic disorder19.03.01.0020.001183%
Grimacing17.02.05.0290.000120%Not Available
Hepatobiliary disease09.01.08.003--Not Available
Hyperlipidaemia14.08.03.0010.000147%
Pigmentation disorder23.05.03.0010.000120%Not Available
Sensorimotor disorder17.05.03.0090.000055%Not Available
Poor quality sleep19.02.05.005; 17.15.04.0020.000202%Not Available
Facial spasm17.04.03.0100.000120%Not Available
Cystitis noninfective20.03.02.001--
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.000164%Not Available
Autism spectrum disorder17.03.05.003; 19.22.02.0020.000174%Not Available
Vulvovaginal mycotic infection21.14.02.004; 11.03.05.004--Not Available
Suicidal behaviour19.12.01.0060.000055%Not Available
Substance abuse19.07.06.0180.000164%Not Available
Liver injury12.01.17.012; 09.01.07.0220.000136%Not Available
Low birth weight baby18.04.02.0030.000082%Not Available
Type 1 diabetes mellitus14.06.01.010; 10.04.08.007; 05.06.01.0100.000082%Not Available
Dementia with Lewy bodies19.20.02.003; 17.03.01.0040.000147%Not Available
Oromandibular dystonia17.01.03.0060.000174%Not Available
Brain injury19.07.03.007; 17.11.01.0030.000082%Not Available
Intellectual disability19.21.06.001; 17.03.07.0010.000147%Not Available
Burning mouth syndrome17.02.06.016; 07.05.05.0130.000120%Not Available
Hypertransaminasaemia09.01.02.0050.000082%Not Available
Fasting26.01.02.001--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
The 23th Page    First    Pre   23 24 25 26    Next   Last    Total 26 Pages